Search Results

There are 136148 results for: content related to: Dose escalation may be effective in patients with psoriasis after treatment failure or suboptimal response, but switching to adalimumab is the most cost-effective measure in different scenarios

  1. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study

    British Journal of Dermatology

    Volume 167, Issue 3, September 2012, Pages: 658–667, C. Leonardi, J.M. Sobell, J.J. Crowley, U. Mrowietz, Y. Bao, P.M. Mulani, Y. Gu and M.M. Okun

    Version of Record online : 20 AUG 2012, DOI: 10.1111/j.1365-2133.2012.11041.x

  2. You have free access to this content
    2016 ACR/ARHP Annual Meeting Abstract Supplement

    Arthritis & Rheumatology

    Volume 68, Issue S10, October 2016, Pages: 1–4550,

    Version of Record online : 8 NOV 2016, DOI: 10.1002/art.39977

  3. You have free access to this content
    Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease

    Alimentary Pharmacology & Therapeutics

    Volume 40, Issue 9, November 2014, Pages: 1044–1055, C. Ma, V. Huang, D. K. Fedorak, K. I. Kroeker, L. A. Dieleman, B. P. Halloran and R. N. Fedorak

    Version of Record online : 3 SEP 2014, DOI: 10.1111/apt.12940

  4. You have free access to this content
    2015 ACR/ARHP Annual Meeting Abstract Supplement

    Arthritis & Rheumatology

    Volume 67, Issue S10, October 2015, Pages: 1–4046,

    Version of Record online : 5 NOV 2015, DOI: 10.1002/art.39448

  5. You have free access to this content
    Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysis

    Alimentary Pharmacology & Therapeutics

    Volume 26, Issue 11-12, December 2007, Pages: 1509–1520, G. G. KAPLAN, C. HUR, J. KORZENIK and B. E. SANDS

    Version of Record online : 11 OCT 2007, DOI: 10.1111/j.1365-2036.2007.03548.x

  6. You have free access to this content
    Adalimumab treatment optimization for psoriasis: Results of a long-term phase 2/3 Japanese study

    The Journal of Dermatology

    Volume 42, Issue 11, November 2015, Pages: 1042–1052, Akihiko Asahina, Mamitaro Ohtsuki, Takafumi Etoh, Yihua Gu, Martin M. Okun, Henrique D. Teixeira, Yuji Yamaguchi and Hidemi Nakagawa

    Version of Record online : 29 JUN 2015, DOI: 10.1111/1346-8138.13001

  7. You have free access to this content
    Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

    Alimentary Pharmacology & Therapeutics

    Volume 31, Issue 12, June 2010, Pages: 1296–1309, R. PANACCIONE, J.-F. COLOMBEL, W. J. SANDBORN, P. RUTGEERTS, G. R. D’HAENS, A. M. ROBINSON, J. CHAO, P. M. MULANI and P. F. POLLACK

    Version of Record online : 18 MAR 2010, DOI: 10.1111/j.1365-2036.2010.04304.x

  8. You have free access to this content
    ACR Meeting

    Arthritis & Rheumatism

    Volume 64, Issue S10, October 2012, Pages: S1–S1216,

    Version of Record online : 11 OCT 2012, DOI: 10.1002/art.37735

  9. You have free access to this content
    Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients

    Alimentary Pharmacology & Therapeutics

    Volume 35, Issue 3, February 2012, Pages: 335–341, E. Bultman, C. de Haar, A. van Liere-Baron, H. Verhoog, R. L. West, E. J. Kuipers, Z. Zelinkova and C. Janneke van der Woude

    Version of Record online : 22 DEC 2011, DOI: 10.1111/j.1365-2036.2011.04946.x

  10. You have free access to this content
    Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients

    Alimentary Pharmacology & Therapeutics

    Volume 29, Issue 3, February 2009, Pages: 273–278, A. SWAMINATH, T. ULLMAN, M. ROSEN, L. MAYER, S. LICHTIGER and M. T. ABREU

    Version of Record online : 22 OCT 2008, DOI: 10.1111/j.1365-2036.2008.03878.x

  11. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept

    British Journal of Dermatology

    Volume 163, Issue 4, October 2010, Pages: 838–846, P.P.M. Van Lümig, L.L.A. Lecluse, R.J.B. Driessen, P.I. Spuls, J.B. Boezeman, P.C.M. Van De Kerkhof and E.M.G.J. De Jong

    Version of Record online : 22 JUL 2010, DOI: 10.1111/j.1365-2133.2010.09950.x

  12. You have free access to this content
    Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease

    Alimentary Pharmacology & Therapeutics

    Volume 28, Issue 9, November 2008, Pages: 1122–1126, R. L. WEST, Z. ZELINKOVA, G. J. WOLBINK, E. J. KUIPERS, P. C. F. STOKKERS and C. J. VAN DER WOUDE

    Version of Record online : 9 AUG 2008, DOI: 10.1111/j.1365-2036.2008.03828.x

  13. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: The first 118 patients

    Inflammatory Bowel Diseases

    Volume 16, Issue 11, November 2010, Pages: 1912–1921, Jason M. Swoger, Edward V. Loftus Jr., William J. Tremaine, William A. Faubion, Darrell S. Pardi, Sunanda V. Kane, Karen A. Hanson, W. Scott Harmsen, Alan R. Zinsmeister and William J. Sandborn

    Version of Record online : 1 APR 2010, DOI: 10.1002/ibd.21272

  14. You have free access to this content
    Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab

    Alimentary Pharmacology & Therapeutics

    Volume 33, Issue 3, February 2011, Pages: 340–348, C. Taxonera, J. Estellés, I. Fernández-Blanco, O. Merino, I. Marín-Jiménez, M. Barreiro-de Acosta, C. Saro, V. García-Sánchez, E. Gento, G. Bastida, J. P. Gisbert, I. Vera, P. Martinez-Montiel, S. Garcia-Morán, M. C. Sánchez and J. L. Mendoza

    Version of Record online : 7 DEC 2010, DOI: 10.1111/j.1365-2036.2010.04531.x

  15. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis

    British Journal of Dermatology

    Volume 167, Issue s3, November 2012, Pages: 12–20, J. Leman and A.D. Burden

    Version of Record online : 22 OCT 2012, DOI: 10.1111/j.1365-2133.2012.11209.x

  16. The effectiveness and safety of adalimumab in the treatment of non-reimbursed patients with mild-to-moderate psoriasis

    Journal of the European Academy of Dermatology and Venereology

    Volume 26, Issue 8, August 2012, Pages: 991–998, H.-Y. Chiu, T.-S. Wang, C.-Y. Chang and T.-F. Tsai

    Version of Record online : 4 AUG 2011, DOI: 10.1111/j.1468-3083.2011.04199.x

  17. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE

    Journal of the European Academy of Dermatology and Venereology

    Volume 25, Issue 9, September 2011, Pages: 1012–1020, J.-P. Ortonne, S. Chimenti, K. Reich, R. Gniadecki, P. Sprøgel, K. Unnebrink, H. Kupper, O. Goldblum and D. Thaçi

    Version of Record online : 9 JAN 2011, DOI: 10.1111/j.1468-3083.2010.03944.x

  18. You have free access to this content
    Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study

    The Journal of Dermatology

    Volume 37, Issue 4, April 2010, Pages: 299–310, Akihiko ASAHINA, Hidemi NAKAGAWA, Takafumi ETOH, Mamitaro OHTSUKI and THE ADALIMUMAB M04-688 STUDY GROUP

    Version of Record online : 26 FEB 2010, DOI: 10.1111/j.1346-8138.2009.00748.x

  19. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial

    British Journal of Dermatology

    Volume 167, Issue 6, December 2012, Pages: 1374–1381, B.E. Strober, J.M. Sobell, K.C. Duffin, Y. Bao, A. Guérin, H. Yang, O. Goldblum, M.M. Okun and P.M. Mulani

    Version of Record online : 2 NOV 2012, DOI: 10.1111/bjd.12000

  20. You have free access to this content
    Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis

    Alimentary Pharmacology & Therapeutics

    Volume 40, Issue 11-12, December 2014, Pages: 1324–1332, F. Baert, N. Vande Casteele, S. Tops, M. Noman, G. Van Assche, P. Rutgeerts, A. Gils, S. Vermeire and M. Ferrante

    Version of Record online : 2 OCT 2014, DOI: 10.1111/apt.12968